These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 35883855)
41. The evaluation of iron overload through hepcidin level and its related factors in myelodysplastic syndromes. Gu S; Song X; Zhao Y; Guo J; Fei C; Xu F; Wu L; Zhang X; Zhao J; Chang C; Li X Hematology; 2013 Sep; 18(5):286-94. PubMed ID: 23540794 [TBL] [Abstract][Full Text] [Related]
42. COVID-19: hemoglobin, iron, and hypoxia beyond inflammation. A narrative review. Cavezzi A; Troiani E; Corrao S Clin Pract; 2020 May; 10(2):1271. PubMed ID: 32509258 [TBL] [Abstract][Full Text] [Related]
43. [Progress in iron metabolism research]. Kawabata H Rinsho Ketsueki; 2017; 58(10):1864-1871. PubMed ID: 28978826 [TBL] [Abstract][Full Text] [Related]
44. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Ganz T Blood; 2003 Aug; 102(3):783-8. PubMed ID: 12663437 [TBL] [Abstract][Full Text] [Related]
45. Relative contribution of iron genes, dysmetabolism and hepatitis C virus (HCV) in the pathogenesis of altered iron regulation in HCV chronic hepatitis. Valenti L; Pulixi EA; Arosio P; Cremonesi L; Biasiotto G; Dongiovanni P; Maggioni M; Fargion S; Fracanzani AL Haematologica; 2007 Aug; 92(8):1037-42. PubMed ID: 17640859 [TBL] [Abstract][Full Text] [Related]
46. Hepcidin levels in hereditary hyperferritinemia: Insights into the iron-sensing mechanism in hepatocytes. Arnold J; Sangwaiya A; Manglam V; Thursz M; Beaumont C; Kannengiesser C; Busbridge M World J Gastroenterol; 2010 Jul; 16(28):3541-5. PubMed ID: 20653062 [TBL] [Abstract][Full Text] [Related]
47. Iron metabolism, hepcidin, and anemia in orthotopic heart transplantation recipients treated with mammalian target of rapamycin. Przybylowski P; Malyszko JS; Macdougall IC; Malyszko J Transplant Proc; 2013; 45(1):387-90. PubMed ID: 23375326 [TBL] [Abstract][Full Text] [Related]
48. Role of non-invasive assessment in prediction of preclinical cardiac affection in multi-transfused thalassaemia major patients. Said Othman KM; Elshazly SA; Heiba NM Hematology; 2014 Oct; 19(7):380-7. PubMed ID: 24225039 [TBL] [Abstract][Full Text] [Related]
49. Dysmetabolic Hyperferritinemia and Dysmetabolic Iron Overload Syndrome (DIOS): Two Related Conditions or Different Entities? Rametta R; Fracanzani AL; Fargion S; Dongiovanni P Curr Pharm Des; 2020; 26(10):1025-1035. PubMed ID: 32003680 [TBL] [Abstract][Full Text] [Related]
50. Serum iron metabolism and erythropoiesis in patients with myelodysplastic syndrome not receiving RBC transfusions. Cui R; Gale RP; Zhu G; Xu Z; Qin T; Zhang Y; Huang G; Li B; Fang L; Zhang H; Pan L; Hu N; Qu S; Xiao Z Leuk Res; 2014 May; 38(5):545-50. PubMed ID: 24598841 [TBL] [Abstract][Full Text] [Related]
51. Effect of hepcidin antagonists on anemia during inflammatory disorders. Sagar P; Angmo S; Sandhir R; Rishi V; Yadav H; Singhal NK Pharmacol Ther; 2021 Oct; 226():107877. PubMed ID: 33895185 [TBL] [Abstract][Full Text] [Related]
52. Serum pro-hepcidin level and iron homeostasis in Japanese dialysis patients with erythropoietin (EPO)-resistant anemia. Shinzato T; Abe K; Furusu A; Harada T; Shinzato K; Miyazaki M; Kohno S Med Sci Monit; 2008 Sep; 14(9):CR431-7. PubMed ID: 18758412 [TBL] [Abstract][Full Text] [Related]
53. Is hepcidin a link between anemia, inflammation and liver function in hemodialyzed patients? Małyszko J; Małyszko JS; Hryszko T; Pawlak K; Mysliwiec M Am J Nephrol; 2005; 25(6):586-90. PubMed ID: 16254410 [TBL] [Abstract][Full Text] [Related]
54. Hepcidin-25, mean corpuscular volume, and ferritin as predictors of response to oral iron supplementation in hemodialysis patients. Takasawa K; Takaeda C; Maeda T; Ueda N Nutrients; 2014 Dec; 7(1):103-18. PubMed ID: 25551249 [TBL] [Abstract][Full Text] [Related]
55. Anemia and iron metabolism in COVID-19: a systematic review and meta-analysis. Taneri PE; Gómez-Ochoa SA; Llanaj E; Raguindin PF; Rojas LZ; Roa-Díaz ZM; Salvador D; Groothof D; Minder B; Kopp-Heim D; Hautz WE; Eisenga MF; Franco OH; Glisic M; Muka T Eur J Epidemiol; 2020 Aug; 35(8):763-773. PubMed ID: 32816244 [TBL] [Abstract][Full Text] [Related]
57. Serum Hepcidin Concentration in Individuals with Sickle Cell Anemia: Basis for the Dietary Recommendation of Iron. Omena J; Cople-Rodrigues CDS; Cardoso JDDA; Soares AR; Fleury MK; Brito FDSB; Koury JC; Citelli M Nutrients; 2018 Apr; 10(4):. PubMed ID: 29673144 [TBL] [Abstract][Full Text] [Related]
58. Hepcidin in trauma: linking injury, inflammation, and anemia. Sihler KC; Raghavendran K; Westerman M; Ye W; Napolitano LM J Trauma; 2010 Oct; 69(4):831-7. PubMed ID: 20938270 [TBL] [Abstract][Full Text] [Related]
59. Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice. Gardenghi S; Ramos P; Marongiu MF; Melchiori L; Breda L; Guy E; Muirhead K; Rao N; Roy CN; Andrews NC; Nemeth E; Follenzi A; An X; Mohandas N; Ginzburg Y; Rachmilewitz EA; Giardina PJ; Grady RW; Rivella S J Clin Invest; 2010 Dec; 120(12):4466-77. PubMed ID: 21099112 [TBL] [Abstract][Full Text] [Related]
60. Study of anemia in nondialysis dependent chronic kidney disease with special reference to serum hepcidin. Goyal H; Mohanty S; Sharma M; Rani A Indian J Nephrol; 2017; 27(1):44-50. PubMed ID: 28182038 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]